Chemo and immunotherapy before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of rectal cancer (a type of colon cancer) that has grown into or through the muscle layer (T3 or T4) and may have spread to nearby lymph nodes (N0–N2), but not to distant organs (M0).
- You are 18 years old or older.
- You are generally in good health – able to do normal activities without help (ECOG score 0 or 1) and have a low surgical risk (ASA grade I–III).
- You have adequate bone marrow, kidney, and liver function based on blood tests done within a few weeks of starting.
- You have not had any other cancer in the last 3 years (except some low-risk skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for locally advanced rectal cancer that combines chemotherapy and radiation with an immunotherapy drug (PD-1 inhibitor) before surgery. The goal is to shrink the tumor and improve the chance of successful surgery and long-term control.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.